DOCSLIB.ORG

Role of Deficient DNA Mismatch Repair Status In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Coordinating Center, NCCTG: N0147 CTSU: N0147 CALGB: N0147 ECOG: N0147 NCIC CTG: CRC.2 SWOG: N0147 North Central Cancer Treatment Group A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer Intergroup Study Chairs Steven R. Alberts, M.D. (Research Base)* Mayo Foundation 200 First Street, SW Rochester, MN 55905 Phone: (507) 284-1328 Fax: (507) 284-5280 E-mail: [email protected] Statisticians Daniel J. Sargent, Ph.D. Mayo Foundation 200 First Street SW Rochester, MN 55905 E-mail: [email protected] Michelle R. Mahoney, M.S. Fax: (507) 266-2477 Phone: (507) 284-8803 * Investigator having NCI responsibility for this protocol. DCTD Supplied Agent via Clinical Supplies Agreement (CSA): Cetuximab (NSC #714692) (Discontinued as of November 25, 2009) Commercial Supplied for patients pre-randomized following the implementation of Addendum 10: Oxaliplatin Document History (Effective Date) Document History (Effective Date) Activation February 10, 2004 NCCTG Addendum 7 January 4, 2008 NCCTG Update 1 February 10, 2004 NCCTG Addendum 8 May 12, 2008 NCCTG Addendum 1 March 29, 2004 NCCTG Addendum 9 August 18, 2008 NCCTG Addendum 2 September 1, 2004 NCCTG Update 3 August 18, 2008 NCCTG Addendum 3 June 1, 2005 NCCTG Addendum 10 May 8, 2009 NCCTG Addendum 4 June 1, 2005 NCCTG Addendum 11 December 18, 2009 NCCTG Addendum 5 August 1, 2005 NCCTG Addendum 12 September 22, 2010 NCCTG Addendum 6 August 15, 2007 NCCTG Addendum 13 June 1, 2011 NCCTG Update 2 August 15, 2007 NCI Version date: April 21, 2011 N0147 2 Addendum 13 Add As of November 25, 2009, all patient enrollments are complete. 3,6,7,9,10,11,1 2,13 Study Co-Chairs NCCTG Suresh G. Nair, M.D. ECOG Emily Chan, M.D. CALGB Richard M. Goldberg, M.D. NCIC CTG Sharlene Gill, M.D. NSABP Morton Kahlenberg, M.D. SWOG Anthony F. Shields, M.D., Ph.D. Laboratory Co-Chair Frank A. Sinicrope, M.D. Mayo Foundation 200 First Street SW Rochester, MN 55905 Phone: (507) 284-4511 Fax: (507) 284-5486 E-mail: [email protected] Thomas C. Smyrk, M.D. (Pathology - Mayo)9 James T. Quesenberry, M.D. (Pathology – NCCTG)9 Thomas A. Webb, M.D. (Pathology – NCCTG)9 Gist Farr, M.D. (Pathology – NCCTG)9 Paul Mazzara, M.D. (Pathology – NCCTG)9 Stephen N. Thibodeau, Ph.D (Laboratory – Research Base)9 9 Study contributor not responsible for patient care. N0147 3 Addendum 13 Protocol Resources (Contact Information) Questions: NCCTG Contact: Add 13 The study protocol and all related forms and documents must be downloaded from the N0147 web page of the CTSU Member web site located at https://www.ctsu.org. Sites must use the current form version and adhere to the instructions and submission schedule outlined in the protocol. CTSU sites should follow procedures outlined in the protocol for Adverse Event Reporting and Data Submission. Submit study data directly to NCCTG NCCTG will manage all data collection processes for this study. Effective June 1, 2011, all NCCTG sites (until August 31, 2011) and all non-NCCTG sites all data and forms are to be mailed directly to: NCCTG Operations Office Attention: Quality Assurance Office (Study N0147) RO FF 03 24-CC/NW Clinic 200 First Street SW Rochester MN 55905 Beginning September 1, 2011, all NCCTG sites will submit all forms via the NCCTG Remote Data Entry System. Do not copy CTSU on any study data or forms submissions. Add Protocol Document, Regulatory Issues NCCTG Research Base Research Protocol Specialists: 3,5,6,8, Angela C. Patterson-LaBaw 10,13 Phone: (507) 538-7339 Fax: (507) 284-5280 E-mail: [email protected] Patricia A. Aggen Phone: (507) 538-6232 Fax: (507) 284-5280 E-mail: [email protected] Add Paraffin-embedded Tissue Pathology NCCTG Research Base Pathology Coordinators: 4,6,7,9, Jennifer Mentlick 11,13 Phone: (507) 293-3928 Fax: (507) 284-1902 E-mail: [email protected] Christine R. Maszk Phone: (507) 266-8919 Fax: (507) 284-1902 E-mail: [email protected] Non-paraffin Biospecimens Roxann Neumann, RN, BSN, CCRP NCCTG Research Base Biospecimen Resource Manager Add Phone: (507) 538-0602 6,9,11 Fax: (507) 266-0824 Email: [email protected] Patient Eligibility or Treatment-Related Questions Lisa Finstuen NCCTG Quality Assurance Specialist Add 2,3,4,5,6,1 Phone: (507) 284-1328 0,13 Fax: (507) 284-1902 E-mail: [email protected] Add Adverse Events Patricia McNamara 10 NCCTG Research Base AdEERS Coordinator Phone: 507/266-3028 Fax: 507/284-9628 E-mail: [email protected] N0147 4 Addendum 13 Protocol Advisors Translational Research Component Investigator: Epidemiology: Frank A. Sinicrope, M.D. Paul J. Limburg, M.D. Mayo Foundation Mayo Foundation 200 First Street SW 200 First Street SW Rochester, MN 55901 Rochester, MN 55901 Phone: (507) 284-8432 Phone: (507) 266-4338 Fax: (507) 284-1803 Fax: (507) 266-0350 E-mail: [email protected] E-mail: [email protected] N0147 5 Addendum 13 Index Schema 1.0 Background 2.0 Goals 3.0 Patient Eligibility 4.0 Test Schedule Add 3,11 5.0 Stratification Factors at the Time of Registration/Randomization Add 9 6.0 Registration/Randomization Procedures (all cooperative groups; also see Appendix XII) 7.0 Protocol Treatment 8.0 Dosage Modification Based on Adverse Events 9.0 Ancillary Treatment 10.0 Adverse Event (AE) Reporting and Monitoring Add 6 11.0 Treatment Evaluation Add 5,9 12.0 Descriptive Factors at the Time of Registration/Randomization 13.0 Treatment/Follow-up Decision at Evaluation of Patient 14.0 Translational/Pharmacologic Studies 15.0 Drug Information 16.0 Statistical Considerations and Methodology 17.0 Pathology Considerations for Quality Control 18.0 Records and Data Collection Procedures 19.0 Budget 20.0 References Add 5,6 Appendix I: Consent Form Appendix II: ECOG Performance Status Appendix III: New York Heart Association Classifications Appendix IV: Patient Instructions for Preventing and Treating Diarrhea Appendix V: Administering Questionnaires: Instructions for Clinical Research Associates (CRAs) – Add 9 Questionnaires are no longer required for patients enrolled following implementation of Addendum 9. Add 7 Appendix VI: Linear Analogue Self Assessment (LASA) Scale - As of Addendum 7, the LASA is no longer required for newly enrolled patients. Appendix VII: Brief Food Questionnaire– Questionnaires are no longer required for patients enrolled following Add 9 implementation of Addendum 9. Appendix VIII: Completion Questions– Questionnaires are no longer required for patients enrolled following Add 9 implementation of Addendum 9. Add 1,6,9 Appendix IX: Focused Health Assessment (Patient Questionnaire) – Questionnaires are no longer required for patients enrolled following implementation of Addendum 9. Add 11 Appendix X: Patient and Physician Fact Sheet – No longer used as of Addendum 11. Appendix XI: NCI/Sanofi-Aventis CRADA Add 13 Appendix XII: Additional N0147 Information Appendix XIII: Blood Specimen Logistics Appendix XIV: Translational Research (also see Sections 14.0 and 17.0) Add 2 Appendix XV: Request Letter for Immunohistochemistry (IHC) Test Results Add 5 Appendix XVI: Dear Participant Letter Add 9,10 Appendix XVII Instrumentation Guide for the DxS KRAS Kits – For use at NCCTG Research Base Only Add 10 Appendix XVIII Quick Reference Guide for Submitting Pathology Materials N0147 6 Addendum 13 Schema Add 9,12 Closed to enrollment, effective November 25, 2009. Arm A – (FOLFOX) Oxaliplatin + 5- fluorouracil/Leucovorin Regimen Oxaliplatin IV over 2 hours x Leucovorin IV over 2 hours x 5-FU IV push Observation Event x 5-FU continuous infusion over 46 hours every 6 months P Monitoring – If Wild Type Repeat for 12 cycles until 5 years Recurrence r until 8 years KRAS following e Randomization randomization from random- - ization R ARM D: FOLFOX + Cetuximab x Oxaliplatin IV over 2 hours a n x Leucovorin IV over 2 hours x 5-FU IV push d x 5-FU continuous infusion over 46 hours o x Cetuximab IV over 2 hours (loading dose) m then weekly IV i z Repeat for 12 cycles a t i If Mutated ARM G: Locally-Directed Therapy o KRAS or Registration x Report summary of therapy n KRAS Not x Annual status reports until 8 years from Evaluable registration Generic name: Oxaliplatin Cetuximab Fluorouracil, Calcium leucovorin, 5-fluorouracil Calcium folinate, Add 2 Citrovorum factor, Folinic acid Brand name: Eloxatin Erbitux Adrucil Leucovorin Mayo abbreviation: OXAL C225 5-FU CF *Blood draws for Section 14.2 must be collected following pre-randomization, prior to registration/randomization (all patients) Add 6,12 and at the time of the first Observation visit, or the next Observation visit for patients already in the Observation phase (Arm A or Arm D patients only). Site must provide NCCTG patient ID that is given at pre-randomization, with the submitted blood samples and on all applicable forms. N0147 7 Addendum 13 1.0 Background 1.1 Disease Incidence and Prognosis 1.11 Colorectal cancers are among the most common malignant tumors in North Americans. 147,300 new cases and 48,100 deaths are anticipated in the United States alone from this disease in 2002 (1). Most patients present with tumors that appear limited to the locoregional area. Those patients undergo resection with curative intent (2-4). Many previous studies have demonstrated that individuals with stage I and early stage II tumors (Modified Astler-Coller A and B1 [T1-2NoMo]) have a >90% 5-year survival. Chemotherapy postoperatively is unnecessary for this favorable prognostic group. However, 40-60% of all patients who undergo resection for potential cure have more advanced locoregional disease.
Recommended publications
  • R262a4 1922.Pdf

    R262a4 1922.Pdf

    -AMERICAN ROAD MAP SUCTCESS First Steps in Psychology . BY FRED S. RAWSON SAN DIEGO, CALIFORNIA Nineteen-Twenty-Two CITY PRINTING CO, 722 Market street, San Diego, California 1 ‘i,, - -t, J , . , SPECIAL NOTICE. For psychological reasons, never loan this book. Keep it for a ready reference for yourself or members of your family. Tell your friends where to get one. But, hold on to your own copy. It is your own private Key to the Temple of Success. Use it daily. It will grow brighter with use. Become familiar with every one of the Thirty-three Elements of Success. Mail orders filled the same day they are received. $1.00, Cloth Bound. THE FREDERICK S. RAWSON PUBLISHING CO. 724 BROADWAY, SAN DIEGO. CALIF. A. K. Aberg, Manager Mail Order Dept. PREFACE. THE ROAD MAP TO SUCCESS, THE PSYCHOLOGICAL CHAIN OF LIFE. All nature grows in silence. All growth is in silence. When you want any new ideas, go where it is quiet; get into the silence, absolute silence. Listen into your own head. When you have adopted this method as a means of getting inspiration, you will never have any trouble getting new ideas. They will come faster than you can write them. I am as positive as I can be, that no person can create anything of any consequence, under fear, excitement, or noise, where constructive thought is required. Have you not heard it said, “For God’s sake, keep still and let me think !“? The idea of the Psychological Chain of Life was received early one morning while lying in bed.
  • Dr Matthew Rimmer Professor of Intellectual Property and Innovation Law Faculty of Law Queensland University of Technology

    Dr Matthew Rimmer Professor of Intellectual Property and Innovation Law Faculty of Law Queensland University of Technology

    MARCH 2016 THE TRANS-PACIFIC PARTNERSHIP: INTELLECTUAL PROPERTY, PUBLIC HEALTH, AND ACCESS TO ESSENTIAL MEDICINES Zahara Heckscher Protests against the TPP DR MATTHEW RIMMER PROFESSOR OF INTELLECTUAL PROPERTY AND INNOVATION LAW FACULTY OF LAW QUEENSLAND UNIVERSITY OF TECHNOLOGY Queensland University of Technology 2 George Street GPO Box 2434 Brisbane Queensland 4001 Australia Work Telephone Number: (07) 31381599 1 Executive Summary This submission provides a critical analysis of a number of Chapters in the Trans-Pacific Partnership addressing intellectual property, public health, and access to essential medicines – including Chapter 18 on Intellectual Property, Chapter 9 on Investment, and Annex 26 on ‘Healthcare Transparency.’ The United States Trade Representative has argued: ‘The Intellectual Property chapter also includes commitments to promote not only the development of innovative, life-saving drugs and treatments, but also robust generic medicine markets.’ The United States maintained: ‘Drawing on the principles underlying the “May 10, 2007” Congressional-Executive Agreement, included in agreements with Peru, Colombia, Panama, and Korea, the chapter includes transitions for certain pharmaceutical IP provisions, taking into account a Party’s level of development and capacity as well as its existing laws and international obligations.’ The United States Trade Representative also argued that the agreement protected public health: ‘The chapter incorporates the Doha Declaration on the TRIPS Agreement and Public Health, and confirms
  • HPSC0011 STS Perspectives on Big Problems Course Syllabus

    HPSC0011 STS Perspectives on Big Problems Course Syllabus

    HPSC0011 STS Perspectives on Big Problems Course Syllabus 2020-21 session | STS Staff, course coordinator Dr Cristiano Turbil | [email protected] Course Information This module introduces students to the uses of STS in solving big problems in the contemporary world. Each year staff from across the spectrum of STS disciplines – History, Philosophy, Sociology and Politics of Science – will come together to teach students how different perspectives can shed light on issues ranging from climate change to nuclear war, private healthcare to plastic pollution. Students have the opportunity to develop research and writing skills, and assessment will consist of a formative and a final essay. Students also keep a research notebook across the course of the module This year’s topic is Artificial Intelligence. Basic course information Moodle Web https://moodle.ucl.ac.uk/course/view.php?id=7420 site: Assessment: Formative assessment and essay Timetable: See online timetable Prerequisites: None Required texts: Readings listed below Course tutor(s): STS Staff, course coordinator Dr Cristiano Turbil Contact: [email protected] | Web: https://moodle.ucl.ac.uk/course/view.php?id=7420 Office location: Online for TERM 1 Schedule UCL Date Topic Activity Wk 1 & 2 20 7 Oct Introduction and discussion of AI See Moodle for details as ‘Big Problem’ (Turbil) 3 21 14 Oct Mindful Hands (Werret) See Moodle for details 4 21 14 Oct Engineering Difference: the Birth See Moodle for details of A.I. and the Abolition Lie (Bulstrode) 5 22 21 Oct Measuring ‘Intelligence’ (Cain & See Moodle for details Turbil) 6 22 21 Oct Artificial consciousness and the See Moodle for details ‘race for supremacy’ in Erewhon’s ‘The Book of the Machines’ (1872) (Cain & Turbil) 7 & 8 23 28 Oct History of machine intelligence in See Moodle for details the twentieth century.
  • The BG News October 28, 2004

    The BG News October 28, 2004

    Bowling Green State University ScholarWorks@BGSU BG News (Student Newspaper) University Publications 10-28-2004 The BG News October 28, 2004 Bowling Green State University Follow this and additional works at: https://scholarworks.bgsu.edu/bg-news Recommended Citation Bowling Green State University, "The BG News October 28, 2004" (2004). BG News (Student Newspaper). 7344. https://scholarworks.bgsu.edu/bg-news/7344 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. This Article is brought to you for free and open access by the University Publications at ScholarWorks@BGSU. It has been accepted for inclusion in BG News (Student Newspaper) by an authorized administrator of ScholarWorks@BGSU. j^k M V Bowling Green State University THURSDAY October 28, 2004 Country looking forward ^^ 1 111 1 PM SHOWERS toIB MAC tourney; PAGE 9 KII I -i-WHN1 A \ \ \< ) HIGH63 LOW48 www.bgnews.com —U VJ ■■" VOLUME 99 ISSUE 56 Political artwork stolen from FAC Six student posters said she feels discouraged and BUSH KERRY fears that the artwork theft were taken last week may hinder students' chances from Fine Arts Center. TWO FLAVORS OF COLA of entering the contest. "It was disrespectful and a violation of their first amend- By lanell Kingsborough SENIOR REPORTER ment rights," Rusnak said. She feels that taking the If il was any other year, the artwork from the display artwork of students in the was one way of silencing the Intermediate Digital Imaging students' voices. course might have lasted longer "Whether people agreed on the wall than one or two with the student's messages days- BOIH BAO (OR vou or not, that did not give Ehem Six posters disappeared last Graphic Created the right to take matters into week from the Fine Arts Center.
  • Thiopurine Drug Therapy

    Thiopurine Drug Therapy

    Thiopurine Drug Therapy Thiopurine drug therapy is used for autoimmune diseases, inflammatory bowel disease, acute lymphoblastic leukemia, and to prevent rejection after solid organ transplant. The inactivation of thiopurine drugs is catalyzed in part by thiopurine Tests to Consider methyltrasferase (TPMT) and nudix hydrolase 15 (NUDT15). Variants in the TPMT and/or NUDT15 genes are associated with an accumulation of cytotoxic metabolites Thiopurine Methyltransferase, RBC leading to increased risk of drug-related toxicity with standard doses of thiopurine 0092066 drugs, and the effects on thiopurine catabolism can be additive. Method: Enzymatic/Quantitative Liquid Chromatography-Tandem Mass Spectrometry The enzyme activity phenotype of TPMT can also be measured directly when Phenotype test to assess risk for severe performed prior to drug administration. Complementary to pretherapeutic tests, myelosuppression with standard dosing of concentrations of thiopurines and metabolites can be measured after initiation of thiopurine drugs therapy to optimize dose. Use for individuals being considered for thiopurine therapy Must be performed before thiopurine therapy is initiated Disease Overview Can also detect rapid metabolizer phenotype Prevalence TPMT and NUDT15 3001535 Method: Polymerase Chain Very low/absent TPMT activity: ~3/1,000 individuals Reaction/Fluorescence Monitoring Intermediate TPMT activity: ~10% of Caucasian individuals Normal TPMT activity: ~90% of individuals Genotyping test to assess genetic risk for severe myelosuppression
  • Program 2018 Barevně

    Program 2018 Barevně

    Pátek Hlavní sál Sci-fi a fantasy Britcom plus Doctor Who Herna 19:00 Zahájení linie + DW kvíz * * * Volné hraní Préza & Gomi Promítání Britcom na p ř ání 20:00 Slavnostní zahájení Alexis Barbucha & Viky The Five(ish) Doctors Reboot / The Curse of Fatal Death / Volné hraní RD: Nachystejte kv ětiná če The Web of Caves 21:00 2000 let stará sci-fi? Vládce jak ho (ne)znáte Geek šperky č ěč Kamil Gregor, Petr Gongala Všechno erné je k n emu dobré Dani-El Daphné Historie Disney Hannibal Jiná dimenze aneb v ědecké teorie Allie Královský bál 22:00 Rok v život ě Johna Barrowmana multiversa (prezentace a hraní) Ziina Vít ězslav Škorpík Kolaps Fawlty Towers: Re-Opened 23:00 RD: Bodysnatcher Lucifer Šipky na kozatou rosni č ku Tezi Mark of Rani * * * Lucy Leveller Herna tým Sobota Hlavní sál Sci-fi a fantasy Britcom plus Doctor Who Herna 9:00 Jak se dabuje Červený trpaslík Apokalypsa a postapo p ř ežívání Kreslení Pythoni Vyrob si svého pana Filutu The End of the World Marty, Jessica & Áda Sherly?! Le fille Ash Tezi 10:00 10 britských seriál ů, Filmové narážky na Doctora Who Č apkový workshop které stojí za to vid ět Doktor Lucerna 11:00 Mistrovství ČR v zírání Č lenská sch ů ze KTP LadyAlex Kohy, Viky, Obscuro Hadati, VeHaLi, Dalila Doctor Who and The Mind of 12:00 Sweeney Todd - cesta legendy Malý rybá ř Nonsense Aludneva Herna tým Scott Lee Hansen 13:00 RD: S12E01 Cured Garth Marenghi´s Darkplace Doktor vál č í Poznej film podle hlášky ě č RD: S12E02 Siliconia Kyberpunkokvý d de ku, Yenn Fritzi DORFL the Sane ě vypráv j… Monty Pythonovy švihlé 14:00 Zdá se, že mám v bidetu žábu Pro č mít rád cynické svin ě Druhý doktor a jeho p ř íb ě hy Ji ří W.
  • Identification and Analysis of Single-Nucleotide Polymorphisms in the Gemcitabine Pharmacologic Pathway

    Identification and Analysis of Single-Nucleotide Polymorphisms in the Gemcitabine Pharmacologic Pathway

    The Pharmacogenomics Journal (2004) 4, 307–314 & 2004 Nature Publishing Group All rights reserved 1470-269X/04 $30.00 www.nature.com/tpj ORIGINAL ARTICLE Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway AK Fukunaga1 ABSTRACT 2 Significant variability in the antitumor efficacy and systemic toxicity of S Marsh gemcitabine has been observed in cancer patients. However, there are 1 DJ Murry currently no tools for prospective identification of patients at risk for TD Hurley3 untoward events. This study has identified and validated single-nucleotide HL McLeod2 polymorphisms (SNP) in genes involved in gemcitabine metabolism and transport. Database mining was conducted to identify SNPs in 14 genes 1Department of Clinical Pharmacy and Pharmacy involved in gemcitabine metabolism. Pyrosequencing was utilized to Practice, Purdue University, W. Lafayette, IN, determine the SNP allele frequencies in genomic DNA from European and 2 USA; Departments of Medicine, Genetics, and African populations (n ¼ 190). A total of 14 genetic variants (including 12 Molecular Biology and Pharmacology, Washington University School of Medicine and SNPs) were identified in eight of the gemcitabine metabolic pathway genes. the Siteman Cancer Center, St Louis, MO, USA; The majority of the database variants were observed in population samples. 3Department of Biochemistry and Molecular Nine of the 14 (64%) polymorphisms analyzed have allele frequencies that Biology, Indiana University School of Medicine, were found to be significantly different between the European and African Indianapolis, IN, USA populations (Po0.05). This study provides the first step to identify markers Correspondence: for predicting variability in gemcitabine response and toxicity. Dr HL McLeod, Washington University The Pharmacogenomics Journal (2004) 4, 307–314.
  • Read Ebook {PDF EPUB} the Man on Platform Five by Robert Llewellyn Robert Llewellyn

    Read Ebook {PDF EPUB} the Man on Platform Five by Robert Llewellyn Robert Llewellyn

    Read Ebook {PDF EPUB} The Man On Platform Five by Robert Llewellyn Robert Llewellyn. Robert Llewellyn is the actor who portrays Kryten from Series III to Series XII. He has also appeared as the presenter of Scrapheap Challenge which ran from 1998-2010 on Channel 4, the host of the web series Carpool which ran from 2009-2014, and as host of the YouTube channel Fully Charged which started in 2010 and still uploads today. Starring on Red Dwarf. Llewellyn's involvement with Red Dwarf came about as a result of his appearance at the Edinburgh Festival Fringe, performing in his comedy, Mammon, Robot Born Of Woman . He was invited to audition for the role of Kryten, by Paul Jackson, before joining the cast for Series III. The story is about a robot who, as he becomes more human, begins to behave increasingly badly. This was seen by Paul Jackson, producer of Red Dwarf , and he was invited to audition for the role of Kryten. Llewellyn joined the cast of Red Dwarf in 1989 at the start of Series III and continued in the role until the end of Series VIII in 1999. His skills as a physical performer encouraged Rob Grant and Doug Naylor to write him additional characters for the series, namely Jim Reaper ("The Last Day"), the Data Doctor ("Back in the Red II"), Human Kryten ("DNA"), Bongo ("Dimension Jump") and Able ("Beyond a Joke"). Llewellyn co- wrote the Red Dwarf Series VII episode "Beyond A Joke" with Doug Naylor. He was also the only British cast member originally to participate in the American version of Red Dwarf , though other actors such as Craig Charles and Chris Barrie were also approached to reprise their roles.
  • Is TPMT Testing a Predictor of Duration of Use Or Long-Term Benefit of Thiopurine Agents? Shatoya R

    Is TPMT Testing a Predictor of Duration of Use Or Long-Term Benefit of Thiopurine Agents? Shatoya R

    Grand Valley State University ScholarWorks@GVSU Masters Theses Graduate Research and Creative Practice 12-2018 Is TPMT Testing a Predictor of Duration of Use or Long-Term Benefit of Thiopurine Agents? Shatoya R. Wilson Grand Valley State University Follow this and additional works at: https://scholarworks.gvsu.edu/theses Part of the Chemical and Pharmacologic Phenomena Commons Recommended Citation Wilson, Shatoya R., "Is TPMT Testing a Predictor of Duration of Use or Long-Term Benefit of Thiopurine Agents?" (2018). Masters Theses. 914. https://scholarworks.gvsu.edu/theses/914 This Thesis is brought to you for free and open access by the Graduate Research and Creative Practice at ScholarWorks@GVSU. It has been accepted for inclusion in Masters Theses by an authorized administrator of ScholarWorks@GVSU. For more information, please contact [email protected]. Is TPMT Testing a Predictor of Duration of Use or Long-Term Benefit of Thiopurine Agents? Shatoya Renee Wilson A Thesis Submitted to the Graduate Faculty of GRAND VALLEY STATE UNIVERSITY In Partial Fulfillment of the Requirements For the Degree of Master of Health Science Biomedical Science December 2018 Dedication This is dedicated to my sister and father, for their support and love. I thank you for listening to me when I needed to practice with or vent to someone. I would also like to dedicate this to my thesis committee, who helped me grow as a student and researcher. For your guidance, I am grateful. 3 Acknowledgements I would like to thank my thesis committee, Dr. Debra Burg, David Chesla, and Dr. John Capodilupo for their mentorship and guidance.
  • Resampling Residuals on Phylogenetic Trees: Extended Results Peter J

    Resampling Residuals on Phylogenetic Trees: Extended Results Peter J

    Resampling Residuals on Phylogenetic Trees: Extended Results Peter J. Waddell1, Ariful Azad2 and Ishita Khan2 [email protected] 1Department of Biological Sciences, Purdue University, West Lafayette, IN 47906, U.S.A. 2Department of Computer Science, Purdue University, West Lafayette, IN 47906, U.S.A . In this article the results of Waddell and Azad (2009) are extended. In particular, the geometric percentage mean standard deviation measure of the fit of distances to a phylogenetic tree are adjusted for the number of parameters fitted on the tree. The formulae are also presented in their general form for any weight that is a function of the distance. The cell line gene expression data set of Ross et al. (2000) is reanalyzed. It is shown that ordinary least squares (OLS) is a much better fit to the data than a Neighbor Joining or BME tree. Residual resampling shows that cancer cell lines do indeed fit a tree fairly well and that the tree does have strong internal structure. Simulations show that least squares tree building methods, including OLS, are strong competitors with BME type methods for fitting model data, while real world examples often suggest the same conclusion. “… his ignorance and almost doe-like naivety is keeping his mind receptive to a possible solution.” A quotation from Kryten: Red Dwarf VIII-Cassandra Keywords: Resampled Residual Bootstrap, flexi-Weighted Least Squares Phylogenetic Trees fWLS, Balanced Minimum Evolution BME, Phylogenomics, Gene Expression Tree Waddell, Azad and Khan (2010). Extended Results of Residual Resampling on Trees Page 1 1 Introduction This article updates and extends some of the results in Waddell and Azad (2010).
  • Recent Topics on the Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities

    Recent Topics on the Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities

    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 29 May 2019 doi:10.20944/preprints201905.0358.v1 Peer-reviewed version available at Int. J. Mol. Sci. 2019, 20, 3210; doi:10.3390/ijms20133210 1 of 39 1 Review 2 Recent topics on the mechanisms of 3 immunosuppressive therapy-related neurotoxicities 4 Wei Zhang 1, Nobuaki Egashira 1,2,* and Satohiro Masuda 1,2 5 1 Department of Clinical Pharmacology and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, 6 Kyushu University, Fukuoka 812-8582, Japan 7 2 Department of Pharmacy, Kyushu University Hospital, Fukuoka 812-8582, Japan 8 * Correspondence: [email protected], Tel.: 81-92-642-5920 9 Abstract: Although transplantation procedures have been developed for patients with end-stagec 10 hepatic insufficiency or other diseases, allograft rejection still threatens patient health and lifespan. 11 Over the last few decades, the emergence of immunosuppressive agents, such as calcineurin 12 inhibitors (CNIs) and mammalian target of rapamycin (mTOR) inhibitors, have strikingly 13 increased graft survival. Unfortunately, immunosuppressive agent-related neurotoxicity is 14 commonly occurred in clinical situations, with the majority of neurotoxicity cases caused by CNIs. 15 The possible mechanisms whereby CNIs cause neurotoxicity include: increasing the permeability 16 or injury of the blood-brain barrier, alterations of mitochondrial function, and alterations in 17 electrophysiological state. Other immunosuppressants can also induce neuropsychiatric 18 complications. For example, mTOR inhibitors induce seizures; mycophenolate mofetil induces 19 depression and headache; methotrexate affects the central nervous system; mouse monoclonal 20 immunoglobulin G2 antibody against cluster of differentiation 3 also induces headache; and 21 patients using corticosteroids usually experience cognitive alteration.
  • Severe Myelotoxicity Associated with Thiopurine S-Methyltransferase*3A

    Severe Myelotoxicity Associated with Thiopurine S-Methyltransferase*3A

    Case Report DOI: 10.4274/tjh.2013.0082 Severe Myelotoxicity Associated with Thiopurine S-Methyltransferase*3A/*3C Polymorphisms in a Patient with Pediatric Leukemia and the Effect of Steroid Therapy Pediatrik Bir Lösemi Olgusunda Tiyopurin S-Metiltransferaz *3A/*3C Polimorfizmi ile İlişkili Ağır Miyelotoksisite-Steroid Tedavisinin Etkisi Burcu Fatma Belen1, Türkiz Gürsel1, Nalan Akyürek2, Meryem Albayrak3, Zühre Kaya1, Ülker Koçak1 1Gazi University Faculty of Medicine, Department of Pediatric Hematology, Ankara, Turkey 2Gazi University Faculty of Medicine, Department of Pathology, Ankara, Turkey 3Kırıkkale University Faculty of Medicine, Department of Pediatric Hematology, Ankara, Turkey Abstract: Myelosuppression is a serious complication during treatment of acute lymphoblastic leukemia and the duration of myelosuppression is affected by underlying bone marrow failure syndromes and drug pharmacogenetics caused by genetic polymorphisms. Mutations in the thiopurine S-methyltransferase (TPMT) gene causing excessive myelosuppression during 6-mercaptopurine (MP) therapy may cause excessive bone marrow toxicity. We report the case of a 15-year-old girl with T-ALL who developed severe pancytopenia during consolidation and maintenance therapy despite reduction of the dose of MP to 5% of the standard dose. Prednisolone therapy produced a remarkable but transient bone marrow recovery. Analysis of common TPMT polymorphisms revealed TPMT *3A/*3C. Key Words: Myelosuppression, Thiopurine S-methyl transferase, Acute leukemia Özet: Miyelosupresyon,